BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties

BRAIN Biotech AG / Key word(s): Contract
BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties

31-Oct-2024 / 19:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR DISSEMINATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties

Zwingenberg, Germany, 31 October 2024 – BRAIN Biotech AG (ISIN DE0005203947; “BRAIN” or “Company”) signed an exclusive technology pharma licensing agreement with Akribion Therapeutics GmbH (“Akribion”) for its genome editing uclease G-dase E®. In exchange for granting exclusivity for pharma applications to Akribion, BRAIN can receive up to EUR 92.3 million R&D and commercial milestone fees. In addition, the company will be entitled to royalties on net sales. The payment structure is based on clinical development progress and market success of Akribion. Akribion is independently owned from the Company and seed financed by venture capital. Non-Pharma related proprietary CRISPR rights remain with BRAIN for commercialization in its core business.

This transaction remains subject to customary closing conditions.

Notifying person:

Martina Schuster

BRAIN Biotech AG

– Investor Relations –

Darmstädter Str. 34-36

64673 Zwingenberg

Deutschland

www.brain-biotech.com

Investor Relations Office

Tel.: +49-(0)-6251-9331-0

Fax: +49-(0)-6251-9331-11

E-Mail: ir@brain-biotech.com

IMPORTANT NOTICE

This announcement may not be published, distributed or released in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia), Australia, Canada, Japan or any other jurisdiction in which the publication, distribution or release would be unlawful. This announcement does not constitute an offer of securities of the company for sale or a solicitation of an offer to purchase securities of the company. There will be no public offer of securities of the Company.

31-Oct-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com